Eli Lilly (LLY) Stock Price Prediction: Strong earnings keep the trend intact, but momentum is stretched

What moved LLY

Eli Lilly’s latest catalyst came from its October 29, 2026 third-quarter report, which showed revenue up 39% year over year to $24.4 billion, led mainly by Mounjaro and Zepbound. The company also raised the midpoint of 2026 full-year revenue guidance by $5.5 billion to a range of $91.0 billion to $92.0 billion and increased underlying non-GAAP EPS guidance at the midpoint by $4.07. Those results support the stock’s current pricing because they confirm that the company’s recent operating strength is still feeding through to forward guidance, not just prior-quarter results. citeturn0search0

Recent analyst updates are consistent with that backdrop, but they do not remove the short-term stretch in the shares. GuruFocus reported that Jefferies maintained a Buy rating on November 9, 2026 and raised its target to $1,700 from $1,610. Investing.com reported on November 2, 2026 that Cantor Fitzgerald raised its target to $1,600 from $1,440 while keeping an Overweight rating. stockanalysis.com says 31 analysts polled by S&P Global have a consensus Buy rating and an average price target of $1,460. The stock is already above that average, so the market is now leaning more on continued execution than on a fresh rerating. citeturn0search1turn0search2turn0search3

Price action and technical structure

LLY closed at $1,482.59, with a 24-hour range of $1,412.12 to $1,491.31 and 24-hour volume of $7,158,896 in the supplied Binance futures data. The share price is above the 7-day SMA at $1,407.69, the 20-day SMA at $1,376.34, and the 50-day SMA at $1,271.50. The EMA stack is also supportive, with the 12-day EMA above the 26-day EMA. Taken together, the trend structure remains bullish. citeturn0search4

The issue is not the direction of the trend, but how far it has already traveled. The RSI at 75.23 and stochastic %K at 94.50 both point to an overbought condition, while price is sitting near the upper Bollinger Band at $1,499.54 with %B at 0.9312. The stock is also more than 5% above the 7-day average and 7.72% above the 20-day average, which fits the supplied note to avoid chasing highs. That combination usually means buyers still have control, but the next leg higher may need fresh support to keep momentum from cooling. citeturn0search4

Derivatives positioning

Binance futures data does not show aggressive leverage expanding into the move. Funding is flat at 0.0000%, which means neither side is paying a clear premium to hold exposure. Open interest fell 8.03% over 24 hours to an open interest value of $2,944,188, which suggests position reduction rather than new leverage building behind the rally. citeturn0search4

The account ratios lean short inside Binance cohorts: global accounts were 44.3% long and 55.7% short, while top-trader accounts were 42.2% long and 57.8% short, both observed at 2026-11-12 10:00 UTC. That does not describe retail versus institutional ownership, but it does show that Binance derivatives participants are not broadly leaning with the price move. At the same time, the taker buy/sell ratio of 1.1698, with buy volume of 597 versus sell volume of 510, shows active buying pressure into the tape. The read-through is mixed: spot-like upward pressure is still visible, but derivatives positioning is not strongly confirming it. citeturn0search4

Key levels

The current pivot is $1,462.01. Above that, immediate resistance is $1,511.89 and stronger resistance is $1,541.20. On the downside, immediate support is $1,432.70, followed by stronger support at $1,382.82. With ATR at $43.31, daily swings are large enough to test these levels without changing the broader trend, so the pivot and the first support zone matter most for near-term direction. citeturn0search4

How to frame LLY here

the evidence supports a stock that is still trend-positive after a strong earnings update, but no longer cheap on short-term momentum. The fundamentals from Lilly’s October 29 report and the recent analyst target increases help explain why the shares remain bid, while the technical and derivatives data argue for caution because price is extended, momentum is overbought, and Binance positioning is not fully aligned with the move. citeturn0search0turn0search1turn0search2turn0search4

A clean break above $1,511.89 would suggest buyers are still willing to absorb supply at higher levels. Failure to hold the $1,462 pivot, especially if the stock loses $1,432.70, would point to a cooling phase rather than an outright trend change.